Emergency response vaccines: Lessons learned in response to communicable diseases

Expert Opinion on Biological Therapy

Volumn 3, Issue 7, 2003, Pages 1121-1131

  Milstien, Julie ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NONE   (France)

Author keywords

Anthrax; Bioterrorism; Emergency; Influenza; Liability; Project Bioshield; Smallpox; Stockpiles

Indexed keywords

ANTHRAX VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLUENZA VACCINE; MALARIA VACCINE; SMALLPOX VACCINE; VACCINE; YELLOW FEVER VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTHRAX; BACTERIAL INFECTION; BIOLOGICAL WARFARE; DRUG COST; DRUG MANUFACTURE; EPIDEMIC; GOOD MANUFACTURING PRACTICE; HEALTH CARE ACCESS; HEALTH CARE POLICY; HUMAN; INFECTION; INFLUENZA; INFLUENZA VACCINATION; MALARIA; MORTALITY; RESOURCE ALLOCATION; REVIEW; SIDE EFFECT; SMALLPOX; TERRORISM; VACCINATION; VIRUS INFECTION; WORLD HEALTH ORGANIZATION; YELLOW FEVER;

COMMUNICABLE DISEASE CONTROL; EMERGENCIES; HUMANS; PUBLIC HEALTH; SMALLPOX VACCINE; TERMINOLOGY; VACCINES;

ANTHRAX; BACTERIA (MICROORGANISMS); HUMAN IMMUNODEFICIENCY VIRUS; VARIOLA VIRUS;

EID: 0142087553     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.3.7.1121     Document Type: Review

References (65)

1. STARK L: Race for a vaccine. ABC News, 11 April, (2003).
2. GLASER CA, GILLIAM S, THOMPSON WW et al.: Medical care capacity for influenza outbreaks, Los Angeles., Emerg. Inf. Dis. (2002) 8:569-574.
3. HENDERSON DA: Biopreparedness and public health. Am. J. Pub. Health (2001) 91:1917-1919.
4. HENDERSON DA, INGLESBY TV, BARTLETT JG et al.: Smallpox as a biological weapon: medical and public health management. JAMA (1999) 281:2127-2137. Consensus recommendations on the use of smallpox vaccines.
5. INGLESBY TV, HENDERSON DA, BARTLETT JG et al.: Anthrax as a biological weapon: medical and public health management. JAMA (1999) 28:1735-1745. Consensus recommendations on the use of anthrax vaccines.
6. INGLESBY TV, O'TOOLE T, HENDERSON DA et al.: Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA (2002) 287:2236-2252. An update on the above article.
7. ARNON SA, SCHECHTER R, INGLESBY TV et al.: Botulinum toxin as a biological weapon: medical and public health management. JAMA (2000) 285:1059-1070.
8. DENNIS DT, INGLESBY TV, HENDERSON DA et al.: Tularemia as a biological weapon: medical and public health management. JAMA (2001) 285:2763-2773.
9. INGLESBY TV, DENNIS DT, HENDERSON DA et al.: Plague as a biological weapon: medical and public health management. JAMA (2000) 283:2281-2290.
10. MILSTIEN J, LAMBERT S: Emergency response vaccines - a challenge for the public sector and the vaccine industry. Vaccine (2002) 21:146-154. Article on which this paper is based, summarising lessons learned from public-private collaboration to handle vaccine supply issues.
11. ROTZ LD, KHAN AS, LILLIBRIDGE SR et al.: Public health assessment of potential biological terrorism agents. Emerg. Inf. Dis. (2002) 8:164-176. The CDCs advisory group classification for prioritisation of activities against possible agents of bioterrorism.
12. GIRI L: Vaccine development for combating bioterrorism and what it means for the vaccine industry. Presentation at World Vaccine Congress Montreal (2002).
13. IAVI: Major contracts awarded for anthrax, malaria vaccines. IAVI Report, October/ November (2002):7.
14. UNITED STATES GENERAL ACCOUNTING OFFICE: Childhood vaccines. Ensuring an adequate supply poses continuing challenges. GAO-02-987 (2002). A comprehensive review of the vaccine supply issues in the US and attempts to deal with it. Useful recommendations on the use of stockpiles.
15. ELLENBERG SS, BRAUN MM: Monitoring the safety of vaccines: assessing the risks. Drug Safety (2002) 25:145-152.
16. NO AUTHORS LISTED: Who will build our biodefences? The Economist February 1 (2003):53-54.
17. FOOD AND DRUG ADMINISTRATION: New drug and biological drug products; evidence needed to demonstrate efficacy of new drugs for use against lethal or permanently disabling toxic substances when efficacy studies in humans ethically cannot be conducted. Federal Register (1999) 64:53960-53970.
18. KAHN P: Accelerating the development of bioterrorism vaccines. An interview with Philip Russell. IAVI Report, October/November (2002):8-11.
19. WECHSLER J: AIDS prevention campaign spotlights biotech. BioPharm International (2003):20-21.
20. WORLD HEALTH ASSEMBLY: Global public health response to natural occurrence, accidental release or deliberate use of biological and chemical agents or radionuclear materials that affect health. WHA 55.16, Geneva (2002).
21. LANE JM, MILLAR JD: Routine childhood vaccination against smallpox reconsidered. N. Engl. J. Med. (1969) 281:1220-1224.
22. WORLD HEALTH ORGANIZATION PRESS OFFICE: Future research on smallpox virus recommended. Press Release WHO/77, December (1999).
23. BROWN J: An integrated biotech business taking novel vaccines from discovery to market. Presentation at World Vaccine Congress, Montreal (2002). Much of the information on the Acambis awards was taken from this reference.
24. FREY SE, COUCH RB, TACKET CO et al.: Clinical responses to undiluted and diluted smallpox vaccine. N. Engl. J. Med. (2002) 346:1265-1274.
25. FREY SE, NEWMAN FK, CRUZ J et al.: Dose-related effects of smallpox vaccine. N. Engl. J. Med. (2002) 346:1275-1280. These two references describe important studies on the current immunogenicity of a vaccine stockpiled for many years.
26. NEFF JM, LANE JM, PERT JH et al.: Complications of smallpox vaccination. I. National surveys in the US. N. Engl. J. Med. (1963) 276:125-132.
27. BICKNELL WJ: The case for voluntary smallpox vaccination. N. Engl. J. Med. (2002) 346:1323-1325.
28. KAPLAN EH, CRAFT DL, WEIN LM: Emergency response to a smallpox attack: the case for mass vaccination. Proc. Natl. Acad. Sci. USA (2002) 99:10935-10940.
29. HALLORAN ME, LONGINI IM JR, NIZAM A, YANG Y: Containing bioterrorist smallpox. Science (2002) 298:1428-1432. Among many studies on how best to use smallpox vaccine in the case of a global threat, this one is perhaps most compelling.
30. BOZZETTE SA, BOER R, BHATNAGER V et al.: A model for a smallpox-vacination policy. N. Engl. J. Med. (2003) 348:416-425.
31. CONNOLLY C: Smallpox plan may force other health cuts. Washington Post, 24 December (2002).
32. CONNOLLY C: US smallpox program lags. Washington Post, 13 April (2003).
33. NO AUTHORS LISTED: Smallpox shots cost about $249 each. Washington Post, 13 April (2003).
34. NO AUTHORS LISTED: Scrambling for safety. The Economist, 30 November (2002):24.
35. GRABENSTEIN JD, WINKENWERDER W: US military smallpox vaccination program experience. JAMA (2003) 289:3278-3282.
36. PAN AMERICAN HEALTH ORGANIZATION: Final report. Meeting on the potential for smallpox vaccine production in the Americas. 19-20 December (2001).
37. ALIBEK K: Biohazard Random House, New York (1999).
38. OBER BT, BRUHL P, SCHMIDT M et al.: Immunogenicity and safety of defective vaccinia virus Lister: comparison with Modified Vaccinia Virus Ankara. J. Virol. (2002) 76:7713-7723.
39. FOOD AND DRUG ADMINISTRATION: Postmarketing studies for approved human drug and licensed biological products; status reports. Federal Register (2000) 65:64607-64619.
40. HALSELL JS, RIDDLE JR, ATWOOD JE et al.: Myopericarditis following smallpox vaccination among vaccination-naïve US military personnel. JAMA (2003) 289:3283-3289.
41. CANCEMI VF: Acute pericarditis after smallpox vaccination. N. Engl. J. Med. (1958) 258:1257-1259.
42. CONNOLLY C: Panel urges caution on smallpox inoculation Washington Post, 20 June (2003). Websites
43. http://www2.eps.gov/spg/HHS/NIH/NIAID/266-02-SARSVAC/Synopsis.html Development of vaccines for severe acute respiratory syndrome; accessed 2 May 2003.
44. http://www.vaccinealliance.org/site-repository/resources/ Executive_Summary_2.doc NINTH GAVI BOARD MEETING, 8. Yellow fever; accessed 4 August 2003.
45. http://www.phacilitate.co.uk/pages/phacilitate/article_fedson.html DAVID FEDSON: The dock is ticking. Interview on Phacilitate Website (2003); accessed 11 April 2003.
46. http://www.whitehouse.gov/news/releases/2003/02/20030203.html THE WHITE HOUSE: President details Project Bioshield. (January 2003); http://www.Sabin.org/PDF/SVR_Nol_Vol6_03.pdf ANONYMOUS: President details Project Bioshield. Sabin Vaccine Report (2003) Spring; accessed 10 September 2003.
47. http://www.whitehouse.gov/news/releases/2003/02/20030203.html THE WHITE HOUSE: President details Project Bioshield. (January 2003); http:// www.Sabin.org/PDF/ SVR_Nol_Vol6_03.pdf ANONYMOUS: President details Project Bioshield. Sabin Vaccine Report (2003) Spring; accessed 10 September 2003.
48. http://www.who.int/vaccines/en/meningococcus.shtml WORLD HEALTH ORGANIZATION: Website for meningitis; accessed 19 April 2003.
49. http://www.who.int/csr/resources/publications/influenza/ WHO_CDS_CSR_EDC_99_1/en WORLD HEALTH ORGANIZATION. Influenza pandemic plan. The role of WHO and guidelines for national and regional planning (1999); accessed 19 April 2003.
50. http://www.infectiousdiseasenews.com/200204/frameset.asp?article=vaccine. asp INFECTIOUS DISEASE NEWS: Waning protection: the fragile vaccine supply, part 1. (2002); accessed 21 April 2003.
51. http://www.unicef.org/pubsgen/vaccines/vaccine-supply.pdf UNICEF: Vaccines for children: supply at risk. United Nations Children's Fund Board (2002); accessed 21 April 2003.
52. th Annual Vaccine Colloquium; accessed 21 April 2003.
53. http://www.who.int/vaccines-surveillance/ISPP/hotQAthiomersal.shtml or http://www.cdc.gov/od/nvpo/thim-qa.htm INSTITUTE OF MEDICINE IMMUNIZATION SAFETY REVIEW COMMITTEE: Report on thimerosal in vaccines; accessed 21 April 2003.
54. http://www.fda.gov/cber/bse/bse.htm CENTER FOR BIOLOGICS RESEARCH AND REVIEW, FDA: Recommendations for the use of vaccines manufactured with bovine-derived materials. (2003); accessed 21 April 2003.
55. http://news.findlaw.com/hdocs/docs/terrorism/hsa2002.pdf UNITED STATES CONGRESS: Homeland security act (HR 5005). (2002); accessed 21 April 2003.
56. http://www.phpab.org/Editorials/ReprintOfParadoxIn.htm MILLAR JD: Paradox in prevention: managing the threat of smallpox bioterrorism. Health Policy Focus (February 2000); accessed 15 April 2003. Useful history of the process up to 2000. Most of the statements in the first part of section 4.1 come from this article.
57. http://www.infectiousdiseasenews.com/200212/smallpox.asp BRYAN BECHTEL: Who will be vaccinated against smallpox; accessed 15 April 2003.
58. http://www.nytimes.com/2002/08/25/ politics/25SMAL.html LAWRENCE K ALTMAN: Health workers await official smallpox policy; accessed 26 August 2002. Note that this version is not the version currently on the website.
59. www.cdc.gov/mmwr/PDF/rr/rr5207.pdf ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES. Healthcare Infection Control Practices Advisory Committee. Recommendations for using smallpox vaccine in pre-event vaccination program: Supplemental recommendations. MMWR (2003) 52(RR-7):1-16; accessed 2003.
60. http://www.bt.cdc.gov/agent/smallpox/vaccination/ vaccination-program-statement.asp THE WHITE HOUSE: Frequently asked questions. Smallpox response teams. (2003); accessed 23 June 2003.
61. http://www.cdc.gov.ncidod/eid/vol7no6/rosenchal.htm ROSENTHAL SR, MERCHLINSKY M, KLEPPINGER C, GOLDENTHAL KL: Developing new smallpox vaccines. Emerg. Inf. Dis. (2001) 7:1-13; accessed 15 April 2003. A summary of FDA policies and guidelines that are essential reading for an understanding of the regulatory issues for smallpox vaccine, but also applicable for other vaccines as well.
62. http://www.fda.gov/cber/letters.htm accessed 2 May 2003.
63. http://www.bt.cdc.gov/agent/smallpox/vaccination/heartproblems.asp; accessed 23 June 2003. See also MCCARTHY M: Heart problems seen in some people receiving smallpox vaccination. The Lancet (2003) 361:1192.
64. http://www.nytimes.com/2003/03/23/business/23VACC.html?tntemail1 POLLACK A, PETERSEN M: Untested companies enlist in US biodefense. The New York Times, 23 March (2003); accessed 24 March, 2003.
65. http://www.bt.cdc.gov/agent/smallpox/response-plan/index.asp US CENTERS FOR DISEASE CONTROL AND PREVENTION: Smallpox Response Plan and Guidelines Draft 3.0 (2003); accessed 2 May 2003.